Right off the bat, Aptose Biosciences (NASDAQ:APTO)
triggers a few warning signals. The company has been around a long time
(since 1986), has had two name changes, and really hasn't accomplished
much of anything. Now this biotech is targeting one of the more
under-served areas of oncology and one that has seen many flame-outs
(most recently Cyclacel (NASDAQ:CYCC).
Coupled with a sub-$100 million market cap and a recent reverse stock
split, a lot of the "beware of" biotech boxes are already checked.
One
of the most dangerous phrases in investing is "it's different this
time", but perhaps in the case of Aptose that is true. This company
cleaned house a while back and brought in credible new senior
management, naming the founder of Achillion (NASDAQ:ACHN)
as its new CEO. The company also raised money and listed itself on the
NASDAQ. Most importantly, though, the company has a drug in its pipeline
that at least appears to have a credible mechanism of action in
treating acute myeloid leukemia - a relatively common type of leukemia,
but one that often has poor expected survival outcomes.
Continue reading here:
Tiny Aptose Biosciences Looks Worth A Closer Look
No comments:
Post a Comment